Literature DB >> 12068084

Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently.

Dominique Massotte1, Karl Brillet, Brigitte Kieffer, Graeme Milligan.   

Abstract

As preferential coupling of opioid receptor to various inhibitory Galpha subunits is still under debate, we have investigated the selectivity of the human mu opioid receptor fused to a pertussis toxin insensitive C351I Gi1 alpha or C352I Gi2 alpha in stably transfected HEK 293 cells. Overall agonist binding affinities were increased for both fusion constructs when compared to the wild type receptor. [35 S]GTPgammaS binding was performed on pertussis toxin treated cells to monitor coupling efficiency of the fusion constructs. Upon agonist addition hMOR-C351I Gi1 a exhibited an activation profile similar to the non-fused receptor while hMOR-C352I Gi2 alpha was poorly activated. Interestingly no correlation could be drawn between agonist binding affinity and efficacy. Upon agonist addition, forskolin-stimulated cAMP production, as measured using a reporter gene assay, was inhibited by signals transduced via the fused Gi1 alpha and Gi2 alpha mainly. In contrast both fusion constructs were able to initiate ERK-MAPK phosphorylation via coupling to endogenous G proteins only. In conclusion our data indicate that hMOR couples more efficiently to Gi1 alpha than Gi2 alpha and that the coupling efficacy is clearly agonist-dependent.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12068084     DOI: 10.1046/j.1471-4159.2002.00946.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  Probing heterotrimeric G protein activation: applications to biased ligands.

Authors:  Colette Denis; Aude Saulière; Segolene Galandrin; Jean-Michel Sénard; Céline Galés
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 2.  Mu-opioid receptor desensitization: is morphine different?

Authors:  Mark Connor; Peregrine B Osborne; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

3.  Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.

Authors:  Peter Heusler; Liesbeth Bruins Slot; Isabelle Rauly-Lestienne; Christiane Palmier; Stéphanie Tardif; Amélie Tourette; Marie-Christine Ailhaud; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-06       Impact factor: 3.000

4.  Differential activation of G-proteins by mu-opioid receptor agonists.

Authors:  Zuzana Saidak; Katherine Blake-Palmer; Debbie L Hay; John K Northup; Michelle Glass
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 5.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

Review 6.  Novel GPCR paradigms at the μ-opioid receptor.

Authors:  G L Thompson; E Kelly; A Christopoulos; M Canals
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 7.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

Review 8.  Effector antagonism by the regulators of G protein signalling (RGS) proteins causes desensitization of mu-opioid receptors in the CNS.

Authors:  Javier Garzón; María Rodríguez-Muñoz; Elena de la Torre-Madrid; Pilar Sánchez-Blázquez
Journal:  Psychopharmacology (Berl)       Date:  2005-04-14       Impact factor: 4.530

9.  Molecular characterization of EG-VEGF-mediated angiogenesis: differential effects on microvascular and macrovascular endothelial cells.

Authors:  Sophie Brouillet; Pascale Hoffmann; Mohamed Benharouga; Aude Salomon; Jean-Patrick Schaal; Jean-Jacques Feige; Nadia Alfaidy
Journal:  Mol Biol Cell       Date:  2010-06-29       Impact factor: 4.138

10.  Agonist-selective signaling is determined by the receptor location within the membrane domains.

Authors:  Hui Zheng; Ji Chu; Yu Qiu; Horace H Loh; Ping-Yee Law
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.